Navigation Links
Bioquark Inc. Announces Approval of Bioquantine Bio-Active Food Additives in Eurasian Customs Union
Date:1/4/2017

Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, announced the commercial approval of naturally derived Bioquantine bio-active food additives in the Eurasian Customs Union (formerly known as the Customs Union of Belarus, Kazakhstan, and Russia). Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, collaborated with Bioquark Inc. on the regulatory approvals.

“We are very excited about this successful regulatory approval,” said Ira S. Pastor, CEO, Bioquark Inc. “The commercialization of Bioquantine bio-active food additives, including in functional foods, drinks, and dietary supplements, represents another important step in our continued evolution as a company focused on a broad range of products and services in the regenerative healthcare space.”

Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.

The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome and virome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.

“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival,” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This Eurasian initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”

About Bioquark, Inc.

Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

Read the full story at http://www.prweb.com/releases/2017/01/prweb13955162.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells
2. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
3. Annual Conference about Technology Solutions for People with Disabilities Announces Program
4. Probiotic Action Announces Probiotics Lead the Digestive Health Market
5. Verenium Announces Preliminary Financial Results For Fiscal 2012
6. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
7. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
8. EAG Announces New General Manager of Release-To-Production (RTP) Division
9. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
10. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
11. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/18/2018)... ... December 18, 2018 , ... Patients with early stages of breast cancer who ... post-treatment versus whole breast irradiation, a new study suggests. , Patients with early stage ... irradiation after removal of the cancerous tumor because there is a 30 to 40 ...
(Date:12/13/2018)... ... 11, 2018 , ... Researchers at Worcester Polytechnic Institute (WPI) ... Clostridium difficile (C. diff), a dangerous and sometimes fatal gastrointestinal infection. The sensor ... used onsite in doctor’s offices and nursing homes, providing results in minutes instead ...
(Date:12/13/2018)... , ... December 12, 2018 , ... Helping conclude Healthy ... new sleek and slim hearing aid within its Vision and Hearing campaign that sets ... , Studies show that despite continued efforts to destigmatize hearing aids over the ...
(Date:12/10/2018)... Shandong, China and SAN DIEGO (PRWEB) , ... ... ... MabPlex International, Ltd., a fully integrated Contract Development and Manufacturing Organization ... line) development, process characterization, conjugation optimization, cGMP manufacturing, and aseptic fill finish ...
Breaking Biology Technology:
(Date:12/19/2018)... (PRWEB) , ... December 19, 2018 , ... NDA Partners ... Reviewer and Compliance Officer at the FDA Center for Devices and Radiological Health (CDRH), ... Partners as an Expert Consultant since 2015, and she has more than 25 years ...
(Date:12/18/2018)... ... 18, 2018 , ... Nativis, Inc. , a clinical ... today announced the publication of an early feasibility study in CNS Oncology suggesting ... The publication of the study, An Early Feasibility Study of the Nativis Voyager® ...
(Date:12/13/2018)... ... 12, 2018 , ... NDA Partners Chief Executive Officer Earle ... Consultants, was recently honored by the American Association of Pharmaceutical Scientists (AAPS) with ... science, technology, engineering, or education and whose contributions to the pharmaceutical sciences community ...
Breaking Biology News(10 mins):